Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
  • Patent number: 12091719
    Abstract: The present disclosure provides a composition comprising a panel of probes for detecting one or more viruses in a sample. The panel of probes may be used to detect viruses in a biological sample obtained from a subject.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 17, 2024
    Assignee: Washington University
    Inventors: Gregory Storch, Todd Wylie, Kristine Wylie
  • Patent number: 11959079
    Abstract: The present disclosure provides a method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele. The method generally involves reducing tau levels in the interneuron.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 16, 2024
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the of Will of J. David Gladstone
    Inventors: Yadong Huang, Yaisa Andrews-Zwilling
  • Patent number: 11891670
    Abstract: Disclosed are probes, primers, a microarray, a kit and applications for rapid detection of clinical microorganism in ophthalmology, belonging to that technical field of clinical microorganism detection. The probes of that disclosure comprise probes for respectively detect Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas aeruginosa, Staphylococcus hominis, Serratia marcescens, Escherichia coli, Bacillus subtilis and Enterobacter cloacae. The disclosure also discloses primers for amplifying the target bacteria, which comprises primers which can amplify gene sequence fragments with intra-species homology of more than 95 percent (%) and inter-species homology of less than 75%. The disclosure also provides a method for synthesizing the hybridization probe on the microarray, a method for hybridization reaction and a method for scanning detection.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: February 6, 2024
    Assignee: AFFILIATED EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY
    Inventors: Yusen Huang, Bining Zhang, Wenfeng Li, Qing Liu, Zhichao Ren, Huabo Chen
  • Patent number: 11879152
    Abstract: This invention describes a method of controlling the hybridization yield of nucleic acid probes by adjusting the relative concentrations of auxiliary oligonucleotides to the probes and the targets. The auxiliary oligonucleotide is partially or fully complementary to either the probe or the target, and is released upon hybridization of the probe to the target.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: January 23, 2024
    Assignee: William Marsh Rice University
    Inventors: David Yu Zhang, Ruojia Wu, Juexiao Wang
  • Patent number: 11767565
    Abstract: Provided are the use of a detection reagent for detecting the methylation of genes associated with colorectal cancer, and a kit. The kit comprises the detection reagent for detecting the methylation of genes associated with colorectal cancer.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: September 26, 2023
    Assignee: WUHAN AMMUNITION LIFE-TECH CO., LTD.
    Inventors: Lianglu Zhang, Tingting Li, Lanlan Dong, Zhicheng Wu, Xihui Yao, Yuzhu Chen
  • Patent number: 11530453
    Abstract: The present disclosure provides, among other things, methods for colorectal cancer, breast cancer, lung cancer and/or pancreatic cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g., next-generation sequencing).
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: December 20, 2022
    Assignee: Universal Diagnostics, S.L.
    Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primoz̆ Knap
  • Patent number: 11505804
    Abstract: Disclosed herein is a unique molecular marker in sorghum genome for conferring broad range fungal resistance trait, and the use of the molecular marker to manipulate resistance in sorghum. A disease resistance gene called ANTHRACNOSE RESISTANCE GENE 1 (ARG1) and a negative regulator, i.e. antisense transcripts of ARG1, called CARRIER OF ARG (CARG) for the fungi resistance gene are knocked out within a quantitative trait locus (QTL).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 22, 2022
    Assignee: Purdue Research Foundation
    Inventors: Tesfaye D Mengiste, Fuyou Fu, Sanghun Lee, Gebisa Ejeta
  • Patent number: 11414715
    Abstract: Provided are methods and mRNA expression chips for identifying genes that are defined by certain nitrogen and water content relationships in soil. The genes can be up or down regulated under low nitrogen or arid conditions to increase the yield or biomass of crops.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: August 16, 2022
    Assignee: New York University
    Inventors: Gloria M. Coruzzi, Joseph Swift
  • Patent number: 11326176
    Abstract: A method of in vivo assembly of a recombinant micelle including: introducing a plasmid into a plant cell, wherein: the plasmid includes a segment of deoxyribonucleic acid (DNA) for encoding a ribonucleic acid (RNA) for a protein in a casein micelle, the segment of DNA is transcribed and translated; forming recombinant casein proteins in the plant cell, wherein: the recombinant casein proteins include a ?-casein and at least one of an ?S1-casein, an ?S2-casein, a ?-casein; and assembling in vivo a recombinant micelle within the plant cell, wherein: an outer layer of the recombinant micelle is enriched with the ?-casein, an inner matrix of the recombinant micelle include at least one of the ?S1-casein, the ?S2-casein, the ?-casein.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: May 10, 2022
    Assignee: MOZZA FOODS, INC.
    Inventor: Cory J. Tobin
  • Patent number: 11274311
    Abstract: This disclosure concerns compositions and methods for promoting transcription of a nucleotide sequence in a plant or plant cell, employing a promoter from a GmTEFs1 gene. Some embodiments relate to a promoter or a 5? UTR from a GmTEFs1 gene that functions in plants to promote transcription of operably linked nucleotide sequences. Other embodiments relate to a 3? UTR or a terminator from a GmTEFs1 gene that functions in plants to promote transcription of operably linked nucleotide sequences.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 15, 2022
    Assignee: Corteva Agriscience LLC
    Inventors: Lyudmila Sidorenko, Cory M. Larsen, Geny Anthony, Shreedharan Sriram, Holly Jean Butler
  • Patent number: 11097134
    Abstract: A method for treating a neurological disorder, symptom or disease that is associated with an increase in the brain levels of caveolin-1 (Cav-1) in a subject in need thereof is disclosed. The method comprises administering to the subject in need thereof a composition comprising: (a) a therapeutically effective amount of an antibody specific against the Cav-1 or an antigen-binding fragment thereof; and (b) a pharmaceutically acceptable carrier. Methods for reducing cerebral inflammation, brain tissue damage, brain neuronal death, and improving behavioral outcomes or functional recovery related to a hemorrhagic stroke in a subject in need thereof are also disclosed.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: August 24, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Song-Kun Shyue, Szu-Fu Chen, Chun-Hu Wu, Che-Feng Chang
  • Patent number: 11098318
    Abstract: The present invention discloses polynucleotide sequences that can be used to regulate gene expression in plants. Terminator sequences from Sorghum bicolor that are functional in plants are disclosed.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: August 24, 2021
    Inventors: Shane E Abbitt, Rudolf Jung
  • Patent number: 10894964
    Abstract: The present invention refers to the use of AT(n) insertions in promoter elements for controlling the expression levels of coding sequences in plants. The expression levels of the heat shock protein (Gmhsp17.6-L), when compared in resistant and susceptible individuals in the population, demonstrated that the largest expression levels per quantitative PCR were present in the individuals that contained the largest AT insertions in the promoter region. The invention also refers to gene expression cassettes containing promoter regions of the gene with different numbers of AT insertions fused to the GUS protein, for transforming soybean embryos.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: January 19, 2021
    Assignee: EMPRESA BRASILEIRA DE PESQUISA AGROPECUARIA - EMBRAPA
    Inventors: Renata Fuganti, Alexandre Lima Nepomuceno, Francismar Correa Marcelino, Joao Flavio Veloso Silva, Silvana Regina Rochenbach Marin, Cesar Augusto Silveira, Eliseu Binneck
  • Patent number: 10731177
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 4, 2020
    Assignees: Vrije Universiteit Brussel, VIB VZW, Universiteit Gent
    Inventors: Thierry Vandendriessche, Marinee Chuah, Pieter De Bleser
  • Patent number: 10676754
    Abstract: The present disclosure includes the production of a mutant plant resistant to an herbicide of the phosphonomethylglycine family, e.g. glyphosate. Compositions and methods are provided for editing a nucleotide sequence of interest in a cell employing a guide polynucleotide/Cas endonuclease system, wherein the Cas endonuclease is guided by a guide polynucleotide to recognize and optionally introduce a double strand break at a specific target site into the genome of a cell. The nucleotide sequence of interest to be edited can be located within or outside the target site that is recognized by a Cas endonuclease. More specifically, compositions and methods are provided for editing an enolpyruvylshikimate-3-phosphate synthase (EPSPS) nucleotide sequence in a cell. The methods and compositions employ a guide polynucleotide/Cas endonuclease system to provide for an effective system for editing EPSPS nucleotide sequences of within the genome of a cell.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 9, 2020
    Assignees: E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Vesna Djukanovic, Spencer Charles Jones, Zhan-Bin Liu, Michael Lassner, Leszek Aleksander Lyznik
  • Patent number: 10612021
    Abstract: The present invention aims to provide a composition for the prevention or treatment of TDP-43 proteinopathy using a microRNA targeting the TDP-43 gene. A prophylactic or therapeutic composition for TDP-43 proteinopathy, comprising: one or more nucleic adds selected from the group consisting of isolated RNAs and isolated nucleic acids encoding the RNAs, wherein the RNAs consist of human miR-33 represented by SEQ ID NO: 1, variants of the human miR-33 having one or more mutations, and precursors of the human miR-33 and the variants.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: April 7, 2020
    Assignee: KYOTO UNIVERSITY
    Inventors: Haruhisa Inoue, Itaru Tsuge, Koh Ono, Shigehiko Suzuki, Motoko Naitoh
  • Patent number: 10533171
    Abstract: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 14, 2020
    Assignee: BioMarin Technologies B.V.
    Inventors: Judith Christina Theodora Van Deutekom, Josephus Johannes De Kimpe, Gerard Johannes Platenburg
  • Patent number: 10519458
    Abstract: The present invention is concerned with the provision of means and methods for gene expression. Specifically, it relates to a polynucleotide comprising an expression control sequence which allows for seed specific of a nucleic acid of interest being operatively linked thereto in plants. Furthermore, vectors, host cells, transgenic plants and methods for expressing nucleic acids of interest are provided which are based on the said polynucleotide.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: December 31, 2019
    Assignee: BASF Plant Science Company GmbH
    Inventors: Huihua Fu, Jeffrey A. Brown, Kirk Francis, Hee-Sook Song
  • Patent number: 10253330
    Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 9, 2019
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Daniel Goldowitz, Charles de Leeuw
  • Patent number: 10227598
    Abstract: Identification of new enhancer sequence has significant utility in the plant functional genomics. The sugarcane bacilliform badnavirus (SCBV) transcriptional enhancer has been identified. This enhancer can be used to increase the rate of transcription from gene promoters and in activation tagging experiments. A ten-fold increase in transcription was observed when a 4× array of the SCBV enhancer was placed upstream of a truncated form of the maize alcohol dehydrogenase minimal promoter. Methods of using the SCBV transcriptional enhancer are described, as are chimeric transcription regulatory regions, constructs, cells, tissues, and organisms that comprise one or more copies of the enhancer.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: John P. Davies, Vaka S. Reddy, William M. Ainley, Mark A. Thompson
  • Patent number: 10167467
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: January 1, 2019
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9982258
    Abstract: The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: May 29, 2018
    Assignee: Devgen NV
    Inventors: Romaan Raemaekers, Pascale Feldmann, Geert Plaetinck, Irene Nooren, Frederic Pecqueur, Laurent Kubler, Nicole Damme, Lies Degrave, Isabel Remory, Thierry Bogaert
  • Patent number: 9970004
    Abstract: Subjects of the invention are: nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG-type repeats. Solution relates to the new concept of treating hereditary human neurological diseases caused by expansion of CAG-type trinucleotide repeats using RNA interference technology.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: May 15, 2018
    Assignee: INSTYTUT CHEMII BIOORGANICZNEJ PAN
    Inventors: Wlodzimierz Krzyzosiak, Marta Olejniczak, Paulina Galka-Marciniak, Agnieszka Fiszer
  • Patent number: 9957555
    Abstract: The invention relates to a method for the detection of the occurrence of initiation of replication events in genomic DNA in a eukaryotic cell, involving contacting said eukaryotic cell comprising said genomic DNA with a first nucleotide probe, under conditions enabling in situ hybridization of said first nucleotide probe with a target region in the DNA genome, wherein said target region comprises a nucleic acid sequence which has no identified corresponding annealing RNA in a metabolically active cell and therefore remains RNA-free during transcription and replication of said DNA genome and detecting said first nucleotide probe hybridized to said DNA. Further detection of at least one RNA molecule can be achieved.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: May 1, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti
  • Patent number: 9951347
    Abstract: The invention provides novel recombinant DNA molecules and constructs useful for modulating gene expression in plants, plant cells, seeds, and progeny plants. Plant regulatory elements comprising sequences from the Ubq10 gene of C. lacryma-jobi, as well as variants and fragments thereof having gene regulatory activity, are provided. The invention also provides transgenic plants, plant cells, plant parts, seeds, and progeny plants comprising the recombinant DNA molecules of the invention, along with methods of their use.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: April 24, 2018
    Assignee: Monsanto Technology LLC
    Inventor: Stanislaw Flasinski
  • Patent number: 9920318
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: March 20, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Scott D. Estes, Weiqun Zhang
  • Patent number: 9879297
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: January 30, 2018
    Assignee: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Patent number: 9850269
    Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: December 26, 2017
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Anusha Dias, Shrirang Karve, Michael Heartlein
  • Patent number: 9803212
    Abstract: The present invention pertains to a method of expressing a protein of interest, preferably a heterologous protein, in preferably a plant. In a preferred embodiment said plant is a doubled haploid homozygous transgenic Nicotiana tabacum plant silenced for Ntp303. Furthermore, the invention relates to said plant with or without nucleic acid constructs according to the invention. Propagation, harvest and tissue material of said transgenic Nicotiana tabacum plant is also a part of the invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: October 31, 2017
    Assignee: R1 B3 Holding B.V.
    Inventors: Marinus Maria Antonius Van Herpen, Jozef Maurinus Raymond Hulzink, Anton Felix Croes
  • Patent number: 9765345
    Abstract: The present invention aims to provide a promoter showing high expression activity in microorganisms belonging to the genus Mortierella. The present invention provides a polynucleotide which contains a nucleotide sequence selected from SEQ ID NOs: 1 to 28, or a variant thereof, as well as a non-human transformant containing such a polynucleotide.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: September 19, 2017
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Misa Ochiai, Jun Ogawa, Eiji Sakuradani, Akinori Ando
  • Patent number: 9631202
    Abstract: The invention provides specific transgenic soybean plants, plant material and seeds, characterized in that these products harbor a specific herbicide tolerance transformation event at a specific location in the soybean genome. Tools are also provided which allow rapid and unequivocal identification of the event in biological samples.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: April 25, 2017
    Assignees: M.S. TECHNOLOGIES LLC, BAYER CROPSCIENCE N.V.
    Inventors: Justin Thomas Mason, Leslie James Lettow, Mark Alan Eby, William H. Eby, Günter Welz, Steven Verhaeghe, Marc De Beuckeleer, Veerle Habex, Jean-Marc Ferrulo
  • Patent number: 9624492
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 18, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9464293
    Abstract: In some embodiments, aptamers that specifically bind pancreatic cancer cells are provided. Such aptamers may include an RNA molecule that specifically binds a pancreatic cancer cell surface protein. In certain embodiments, the RNA molecule that is used as an aptamer may include a nucleotide sequence of GAAUGCCC (SEQ ID NO: 8). In other embodiments, the RNA molecule may include a nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. In certain embodiments, the aptamer may be conjugated to one or more therapeutic agents (e.g., an shRNA molecule, an siRNA molecule, an mRNA molecule, or an miRNA molecule), one or more diagnostic agents, or a combination thereof. The aptamers and their conjugates may be used to deliver therapeutic agents to a pancreatic cancer cell, and/or in methods for treating or diagnosing pancreatic cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 11, 2016
    Assignee: CITY OF HOPE
    Inventors: John J. Rossi, Sorah Yoon
  • Patent number: 9447419
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 20, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • Patent number: 9428815
    Abstract: The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: August 30, 2016
    Assignee: Emory University
    Inventor: Raymond F. Schinazi
  • Patent number: 9410159
    Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: August 9, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
  • Patent number: 9403887
    Abstract: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 2, 2016
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Livnat Bangio, Reshef Tal
  • Patent number: 9334539
    Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: May 10, 2016
    Assignees: The Hospital for Sick Children, McGill University, The Regents of the University of California, U.S. Department of Veterans Affairs
    Inventors: Stephen W. Scherer, Berge A. Minassian, Antonio Delgado-Escueta, Guy Rouleau
  • Patent number: 9333218
    Abstract: The disclosure relates to microRNAs (miRNAs) for the prophylaxis and/or treatment of neoplasia. The disclosure relates in particular to sequence corresponding to miR2 and the miR-548 family, including precursors, mature forms, fragments, and combinations thereof for the prophylaxis and/or treatment of neoplasias, particularly lung, stomach, and cervical cancer, alone or in combination with additional cancer treatments and therapeutics.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: May 10, 2016
    Assignee: Emory University
    Inventors: Ya Wang, Baocheng Hu, Walter J. Curran
  • Patent number: 9322028
    Abstract: Non-naturally occurring DNA promoters, include MSGT-PFlt, PFlt-UAS-2X and FSgt-PFlt. The MSGT-PFlt was developed and has expression shown to be equivalent to that of CaMV35S promoter. DNA promoters PFlt-UAS-2X and FSgt-PFlt were developed and tested in transient and transgenic system and found to be stronger than the CaMV35S promoter.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: April 26, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Indu Maiti, Nrisingha Dey
  • Patent number: 9303266
    Abstract: The invention provides novel recombinant DNA molecules and constructs useful for modulating gene expression in plants, plant cells, seeds, and progeny plants. The invention also provides transgenic plants, plant cells, plant parts, seeds, and progeny plants comprising the recombinant DNA molecules of the invention, along with methods of their use.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 5, 2016
    Assignee: Monsanto Technology LLC
    Inventor: Stanislaw Flasinski
  • Patent number: 9297019
    Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 29, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
  • Patent number: 9297018
    Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 29, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
  • Patent number: 9198927
    Abstract: The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: December 1, 2015
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Daniel E. McCallus, Catherine Pachuk, Baohua Gu
  • Patent number: 9187757
    Abstract: The subject invention concerns materials and methods for modulating lignin biosynthesis in sugarcane plants. In one embodiment, lignin biosynthesis is down-regulated. Genes and the proteins encoded thereby that can be targeted for achieving down-regulation of lignin in sugarcane include, for example, 4-coumarate-CoA ligase (4CL). In one embodiment, the 4CL gene is 4CL-M, 4CL-N, or 4CL-L. The subject invention also concerns a sugarcane plant, specific plant tissue, and plant cells having modulated (e.g., down-regulated) lignin biosynthesis. The subject invention also concerns methods for producing a sugarcane plant having modulated (e.g., decreased or down-regulated) biosynthesis of lignin.
    Type: Grant
    Filed: June 5, 2010
    Date of Patent: November 17, 2015
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Fredy Altpeter, Walid Mohamed Fouad, Maria Gallo, Je Hyeong Jung, Yuan Xiong
  • Patent number: 9163250
    Abstract: The invention found that partial deletion of the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter can enhance gene expression (even heterologous gene expression) in basidiomycetous fungi. With the discovery of these gpd promoters, an expression system can be constructed for the expression of a heterologous gene in mushroom. Accordingly, the invention provides a truncated glyceraldehyde-3-phosphate dehydrogenase promoter and a construct comprising the promoter of the invention operably linked to a heterologous transcribable polynucleotide molecule and a mushroom comprising the construct.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: October 20, 2015
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Ying-Tzu Lyu
  • Patent number: 9096878
    Abstract: The present inventors conducted dedicated studies and successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired dihydrofolate reductase gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: August 4, 2015
    Assignees: National University Corporation Hokkaido University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Hiroshi Tahara, Yusuke Suzuki, Keiichi Yamamoto, Yuzuru Kitahara, Yasuhiko Suzuki
  • Patent number: 9096637
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 4, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • Patent number: 9056886
    Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 16, 2015
    Assignee: APTABIO THERAPEUTICS INC.
    Inventors: Soo Jin Lee, Sung Hwan Moon
  • Publication number: 20150147782
    Abstract: The present invention relates to a light-inducible promoter and a gene expression system containing the same, and provides: a light-inducible promoter comprising a nucleotide sequence represented by SEQ ID NO: 12; and a method for producing heterologous proteins using the same. Since the light-inducible promoter of the present invention induces the expression of a gene by the irradiation of light and regulates an expression amount of the gene according to an intensity of light, it is possible to conveniently regulate the expression of the gene without straining the growth or metabolic process of an organism. In addition, the present invention can be applied to various types of organisms, and thus has a wide range of application.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 28, 2015
    Inventors: Eon Seon Jin, Jae Hyeok Lee, Seung Hye Park, Kwang Ryul Baek